Quantum Leap Healthcare Collaborative

I-SPY in the News

Widely hailed as the future of phase II drug development, the adaptive I-SPY2 platform trial has set a new benchmark for efficiency, through innovation in trial design and clinical operations.

MammaPrint and BluePrint's use in Personalizing Neoadjuvant Treatment Approaches for Early-Stage Breast Cancer Patients

Media Contact:

Jeff Matthews, PhD
University of California San Francisco
jmatthews@ispy2.org